Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting ItemsEfficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials.
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Usmani S, Facon T, Moreau P, Dimopoulos M, Mateos M, Costa L. Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials. Journal Of Clinical Oncology 2020, 38: 8540-8540. DOI: 10.1200/jco.2020.38.15_suppl.8540.Peer-Reviewed Original ResearchHigh-risk cytogeneticsProgression-free survivalPhase III trialsMultiple myelomaR settingIII trialsMature overall survival dataDerSimonian-Laird random-effects modelPhase III randomized trialsRandomized phase III trialFirst-line settingOverall survival dataImproved response ratesRandom-effects modelLog hazard ratioBackbone regimenBackbone regimensHRC patientsRefractory settingPrimary endpointSame regimenFree survivalCytogenetic riskMM patientsRandomized trials